These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8218941)

  • 21. Production of prostaglandin E2 and collagenase is inhibited by the recombinant soluble tumour necrosis factor receptor p55-human gamma 3 fusion protein at concentrations a hundred-fold lower than those decreasing T cell activation.
    Nicod LP; Isler P; Chicheportiche R; Songeon F; Dayer JM
    Eur Cytokine Netw; 1996 Dec; 7(4):757-63. PubMed ID: 9010678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification, characterization, and cloning of TIP-B1, a novel protein inhibitor of tumor necrosis factor-induced lysis.
    Berleth ES; Nadadur S; Henn AD; Eppolito C; Shiojiri S; Gurtoo HL; Ehrke MJ; Mihich E
    Cancer Res; 1999 Nov; 59(21):5497-506. PubMed ID: 10554026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of cytokines in osteoarthritis pathophysiology.
    Fernandes JC; Martel-Pelletier J; Pelletier JP
    Biorheology; 2002; 39(1-2):237-46. PubMed ID: 12082286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteoarthritic synovial fibroblasts possess an increased level of tumor necrosis factor-receptor 55 (TNF-R55) that mediates biological activation by TNF-alpha.
    Alaaeddine N; DiBattista JA; Pelletier JP; Cloutier JM; Kiansa K; Dupuis M; Martel-Pelletier J
    J Rheumatol; 1997 Oct; 24(10):1985-94. PubMed ID: 9330943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transforming growth factor-beta suppresses tumor necrosis factor alpha-induced matrix metalloproteinase-9 expression in monocytes.
    Vaday GG; Schor H; Rahat MA; Lahat N; Lider O
    J Leukoc Biol; 2001 Apr; 69(4):613-21. PubMed ID: 11310848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TNF alpha and the TNF receptor superfamily: structure-function relationship(s).
    Idriss HT; Naismith JH
    Microsc Res Tech; 2000 Aug; 50(3):184-95. PubMed ID: 10891884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammation-related neutrophil proteases, cathepsin G and elastase, function as insulin-like growth factor binding protein proteases.
    Gibson TL; Cohen P
    Growth Horm IGF Res; 1999 Aug; 9(4):241-53. PubMed ID: 10512690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome.
    Jit M; Henderson B; Stevens M; Seymour RM
    Rheumatology (Oxford); 2005 Mar; 44(3):323-31. PubMed ID: 15585509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin.
    Lantz M; Thysell H; Nilsson E; Olsson I
    J Clin Invest; 1991 Dec; 88(6):2026-31. PubMed ID: 1752960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TNF: a master switch for inflammation to cancer.
    Sethi G; Sung B; Aggarwal BB
    Front Biosci; 2008 May; 13():5094-107. PubMed ID: 18508572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential biological and clinical significance of the soluble tumor necrosis factor receptors.
    Aderka D
    Cytokine Growth Factor Rev; 1996 Oct; 7(3):231-40. PubMed ID: 8971478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon.
    Solorzano CC; Kaibara A; Hess PJ; Edwards PD; Ksontini R; Abouhamze A; McDaniel S; Frazier J; Trujillo D; Kieft G; Seely J; Kohno T; Cosenza ME; Clare-Salzler M; MacKay SL; Martin SW; Moldawer LL; Edwards CK
    J Appl Physiol (1985); 1998 Apr; 84(4):1119-30. PubMed ID: 9516174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumour necrosis factor and cancer.
    Balkwill F
    Nat Rev Cancer; 2009 May; 9(5):361-71. PubMed ID: 19343034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A physicochemical modelling approach for estimating the stability of soluble receptor-bound tumour necrosis factor-alpha.
    Ramanathan M
    Cytokine; 1997 Jan; 9(1):19-26. PubMed ID: 9067092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour necrosis factor and cancer.
    Balkwill FR
    Prog Growth Factor Res; 1992; 4(2):121-37. PubMed ID: 1338573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble forms of cytokine and growth factor receptors: mechanisms of generation and modes of action in the regulation of local and systemic inflammation.
    Kefaloyianni E
    FEBS Lett; 2022 Mar; 596(5):589-606. PubMed ID: 35113454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viral TNF inhibitors as potential therapeutics.
    Rahman MM; Lucas AR; McFadden G
    Adv Exp Med Biol; 2009; 666():64-77. PubMed ID: 20054975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble cytokine receptors: basic immunology and clinical applications.
    Fernandez-Botran R
    Crit Rev Clin Lab Sci; 1999 Jun; 36(3):165-224. PubMed ID: 10407682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two tumour necrosis factor receptors: structure and function.
    Vandenabeele P; Declercq W; Beyaert R; Fiers W
    Trends Cell Biol; 1995 Oct; 5(10):392-9. PubMed ID: 14732063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammation as a Precursor of Tumour Formation.
    Hospital (Lond 1886); 1900 Dec; 29(744):226. PubMed ID: 29813537
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.